MANNHEIM, Germany — A novel drug that targets production of a liver protein involved in lipid metabolism appears to markedly reduce low-density lipoprotein (LDL) cholesterol levels for patients with ...
RNA interference (RNAi) technology has gradually become a cutting-edge technology for treating diseases such as genetic disorders and cancer due to its huge potential in gene expression regulation.
Morning Overview on MSN
A single shot just slashed dangerous cholesterol levels for a full year in a late-stage trial — a gene-silencing therapy built to replace the daily statins millions take
For the roughly 200 million people worldwide who take a statin every day, the routine is deceptively simple: swallow a pill, ...
SCTIMST performs its first LDL apheresis for Familial Hypercholesterolemia, dramatically lowering cholesterol in a 34-year-old patient.
Morning Overview on MSN
A single gene-silencing shot just cut dangerous cholesterol in half for a full year — built to replace the daily statins millions of adults already take
Roughly 40 million adults in the United States take a statin pill every day to keep their cholesterol in check, according to ...
Basel, March 28, 2020 — Novartis today announced results from a prespecified analysis of pooled data from three Phase III studies evaluating the safety and efficacy of inclisiran, its first-in-class ...
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1 Leqvio provides effective and sustained LDL-C ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results